Last updated: February 15, 2026
Overview
The National Drug Code (NDC) 00173-0676 corresponds to Latanoprost Ophthalmic Solution, a branded medication primarily used to lower intraocular pressure in glaucoma and ocular hypertension. The drug is marketed under the brand Xalatan by Pfizer. The analysis covers market dynamics, competitive landscape, regulatory environment, and pricing strategies.
Market Size and Demand
Global glaucoma treatment market was valued at approximately $5 billion in 2022 with an expected compound annual growth rate (CAGR) of roughly 4% through 2027 [1]. Latanoprost holds a significant share within prostaglandin analogs, accounting for around 35-40% of prescriptions in this class in the U.S. [2].
Domestically, in the U.S., estimated annual sales for Xalatan totaled approximately $600 million in 2022, representing a stable demand pattern. Factors influencing demand include:
- Aging population with increased glaucoma prevalence (estimated 3 million Americans age 40+ live with glaucoma).
- Higher adoption rate due to superior efficacy and tolerability over older therapies.
- Competitive entries, including generics and alternative formulations.
Competitive Landscape
The market features multiple prostaglandin analogs:
- Bimatoprost (Lumigan): Competitive with similar efficacy.
- Travoprost (Travatan Z): Alternative option, slightly lower market share.
- Generic Latanoprost: Entered market in 2019 after patent expiry, with prices significantly lower than Xalatan.
Brand-name formulations like Xalatan maintain premium pricing owing to brand loyalty, physician preference, and formulary positioning. However, the entry of generics pressurizes prices.
Regulatory Status
Xalatan's patent protections expired in 2019, enabling generic manufacturing. Several companies now produce generic latanoprost, causing a notable decline in the average price of prescribed latanoprost.
Pfizer retains exclusivity through methods such as patent extensions and formulation patents, but these have been challenged or expired, impacting pricing power.
Pricing Trends and Projections
Current retail price per 2.5 mL bottle (prescribed dose: once nightly) averages around $150-160 retail. Wholesale acquisition costs (WAC) are approximately $120-130. Generic versions retail for approximately $20-50, reflecting a 70-85% discount compared to branded.
Projection assumptions:
- Patent expiry and generic competition are likely to sustain price erosion.
- The average price for branded Xalatan is expected to decline by 10-20% annually over the next 3 years.
- The generic segment could capture 25-35% of the market share within the same period, further diminishing the branded product's revenue.
By 2026, branded product prices might settle near $120 per bottle, while generics could stabilize around $15-$25. Total market share for branded formulations could shrink to less than 20%, with generics dominating the volume.
Revenue Projections
Estimated U.S. sales (assuming 2-3 million bottles sold annually):
| Year |
Branded Revenue |
Generic Revenue |
Total Market Size |
| 2023 |
$180-220 million |
$30-50 million |
$210-270 million |
| 2024 |
$160-200 million |
$45-70 million |
$205-270 million |
| 2025 |
$140-180 million |
$70-100 million |
$210-280 million |
These figures assume stable prescription volumes but declining average prices.
Key Factors Influencing Future Prices
- Patent litigation outcomes and patent term extensions.
- Regulatory approvals for biosimilar or alternative formulations.
- Reimbursement policies and insurance coverage.
- Prescriber and patient preferences shifting toward or away from branded medications.
Conclusion
The branded drug (Xalatan) faces increasing pricing pressure from generic competition, with a projected sustained decline in price over the next three years. Market shares will increasingly shift toward generics, reducing the revenue potential for Pfizer and similar brand manufacturers. The overall glaucoma treatment market is poised for moderate growth but limited by price erosion in prostaglandin analogs.
Key Takeaways
- The U.S. glaucoma medication market is around $5 billion.
- Branded latanoprost prices are expected to decline by 10-20% annually through 2026.
- Generics will command the majority market share, with prices around $15-$25.
- Revenue for the branded product could decrease by approximately 30% over three years.
- Patent expirations and regulatory actions will shape future pricing dynamics.
FAQs
-
When did patent expiry occur for Xalatan?
- Patent protection for the original formulation expired in 2019, enabling generic competition.
-
What factors could accelerate the decline in branded drug prices?
- Introduction of additional generics, patent litigation outcomes, and formulary shifts favoring lower-cost alternatives.
-
How does the market share for generics compare to branded Xalatan?
- Generics are expected to account for over 75% of prescriptions by 2025.
-
Are biosimilars or alternative formulations emerging?
- No biosimilars exist for latanoprost, but alternative delivery systems or formulations are under investigation.
-
What is the impact of insurance coverage on pricing?
- Insurance and formulary preferences strongly influence patient out-of-pocket costs and prescribing patterns.
Sources
[1] Grand View Research, "Glaucoma Treatment Market Size & Trends," 2022.
[2] IQVIA, Prescription Data, 2022.
[3] FDA, "Approved Drug Products with Therapeutic Equivalence Evaluations," 2022.
[4] IQVIA, "Generic Drug Trends," 2022.
